AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot
Eoneren/E+ via Getty Images


U.K.-based biotech Oxford Biomedica (OTCPK:OXBDF) announced on Friday that the company entered into a new three-year partnership with AstraZeneca (AZN) to manufacture the Anglo Swedish pharma giantâs COVID-19 vaccine.
The deal marks an expansion of the original agreement the companies signed in Sep. 2020 for the vector-based shot.

Per the terms of the new Master Services & Development Agreement, Oxford Biomedicaâs (OTCPK:OXBDF) 84,000 sq. ft manufacturing facility, Oxbox, will be made available for AstraZeneca (AZN) to manufacture vaccines as needed beyond 2022.
According to the original deal and including the revenue for vaccine batches already manufactured during 1H 2022, Oxford Biomedicaâs (OTCPK:OXBDF) expects to recognize Â£30M revenue from AstraZeneca (AZN) in the current financial year.
AstraZenecaâs (AZN) COVID-19 vaccine generated ~$1.2B sales in 1Q 2022.